Northwestern's NU-9 Drug Prevents Alzheimer's Pathology in Pre-Symptomatic Animal Model
核心洞察
Northwestern University researchers discovered that experimental drug NU-9 dramatically reduces toxic amyloid beta oligomers (搜索) and prevents early brain inflammation in pre-symptomatic Alzheimer's disease (搜索) mouse models.
The study identified a previously unknown highly toxic amyloid beta oligomer subtype called ACU193+ that appears to drive neuronal dysfunction and inflammation decades before symptoms emerge.
NU-9 demonstrated brain-wide anti-inflammatory effects by significantly reducing reactive astrogliosis and abnormal TDP-43 protein accumulation after 60 days of daily oral treatment.
Northwestern University scientists have demonstrated that an experimental small-molecule drug called NU-9 can halt the earliest pathological changes of Alzheimer's disease (搜索) in animal models, offering new hope for preventing the neurodegenerative condition before symptoms appear.
Published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, the study reveals that NU-9 dramatically reduced toxic protein accumulation and brain inflammation in pre-symptomatic mice, addressing the disease decades before cognitive decline typically emerges.
Novel Toxic Protein Subtype Identified
The research team identified a previously unknown highly toxic subspecies of amyloid beta oligomers (搜索) that appears to drive several of the brain's earliest pathological changes, including neuronal dysfunction, inflammation, and immune cell activation. This subtype, designated ACU193+ because it is detected by the antibody ACU193, shows up early inside stressed neurons before migrating to nearby astrocytes (搜索).
"We identified a distinct amyloid beta oligomer subtype that appears inside neurons and on nearby reactive astrocytes (搜索) very early in the disease," said Daniel Kranz, the study's first author and recent Northwestern PhD graduate. "It potentially acts as an instigator of early Alzheimer's pathology."
When ACU193+ oligomers bind to astrocytes (搜索), they may trigger a cascade of inflammation that spreads throughout the brain long before memory loss begins, the researchers found.
Striking Pre-Symptomatic Results
In the study, researchers administered NU-9 as a daily oral dose for 60 days to pre-symptomatic mouse models of Alzheimer's disease (搜索). The results demonstrated multiple therapeutic benefits across brain regions.
NU-9 significantly reduced early reactive astrogliosis, an inflammatory reaction that typically begins long before symptoms appear. The number of toxic amyloid beta oligomers (搜索) bound to astrocytes (搜索) also plummeted, while abnormal TDP-43 protein—a hallmark of neurodegenerative diseases linked to cognitive impairments—sharply decreased.
"These results are stunning," said William Klein, professor of neurobiology at Northwestern and corresponding author. "NU-9 had an outstanding effect on reactive astrogliosis, which is the essence of neuroinflammation and linked to the early stage of the disease."
The improvements spanned multiple brain regions, indicating that NU-9 has a brain-wide anti-inflammatory effect.
Mechanism of Action
NU-9 works by rescuing cellular pathways responsible for clearing toxic protein aggregates. According to Klein, cells have natural mechanisms to eliminate these proteins, but these systems become damaged in degenerative diseases like ALS (搜索) and Alzheimer's.
"In both ALS (搜索) and Alzheimer's disease (搜索), cells suffer from toxic protein buildup," Klein explained. "NU-9 is rescuing the pathway that saves the cell."
The drug specifically targeted and dramatically reduced the ACU193+ oligomer subtype, suggesting it may be especially valuable at Alzheimer's earliest stages when intervention is most effective.
Prophylactic Potential
The researchers envision NU-9 functioning as a prophylactic treatment, similar to cholesterol-lowering medications for heart disease prevention. Individuals with biomarkers indicating Alzheimer's risk could potentially begin treatment before symptoms develop.
"Most people are used to monitoring their cholesterol levels," said Richard Silverman, who invented NU-9 and previously developed pregabalin (Lyrica). "If you have high cholesterol, it doesn't mean that you will have a heart attack soon. But it's time to take drugs to lower your cholesterol levels to prevent that heart attack from happening down the road. NU-9 could play a similar role."
Clinical Development Timeline
NU-9 emerged from Silverman's 15-year effort to discover small molecule compounds that could prevent toxic protein aggregate buildup in neurodegenerative diseases. The drug demonstrated efficacy in ALS (搜索) animal models by 2021, clearing toxic SOD1 (搜索) and TDP-43 proteins and restoring upper motor neuron health. In 2024, NU-9 received FDA clearance to begin human clinical trials for ALS.
Earlier this year, the research team demonstrated that NU-9 could effectively clear toxic amyloid beta oligomers (搜索) in lab-grown hippocampal brain cells, a region critical for learning and memory.
Addressing Clinical Trial Failures
The pre-symptomatic approach addresses a critical limitation in previous Alzheimer's clinical trials, which have largely failed due to late-stage intervention.
"Alzheimer's disease (搜索) begins decades before its symptoms appear, with early events like toxic amyloid beta oligomers (搜索) accumulating inside neurons and glial cells becoming reactive long before memory loss is apparent," Kranz noted. "By the time symptoms emerge, the underlying pathology is already advanced. This is likely a major reason many clinical trials have failed. They start far too late."
Future Research Directions
The team is currently testing NU-9 in additional Alzheimer's disease (搜索) models, including late-onset disease models that better reflect typical human aging. Researchers plan to follow animals for longer periods to determine whether symptoms develop in treated animals and examine how early intervention affects memory and neuron health over time.
Klein emphasized the potential synergy between improved early diagnostics and preventive therapeutics: "There are a couple early diagnostic blood tests for Alzheimer's disease (搜索) in development. The promise of better early diagnostics—combined with a drug that could stop the disease in its tracks—is the goal."
The study was supported by the National Institutes of Health, and the research team has disclosed financial interests in Akava Therapeutics (搜索) and Acumen Pharmaceuticals, companies commercializing related therapeutic approaches.